Direct oral anticoagulants (DOACs), such as rivaroxaban, reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). However, it is still …

Background: Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF)
include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal …

Background The risk factors that have been identified for bleeding events with rivaroxaban
are predominantly the same as those predicting thromboembolic ones in patients with atrial …

Introduction Atrial fibrillation (AF) is the most common arrhythmia, with an estimated
prevalence between 1–4%. On the other hand, obesity continued to be a prevalent health …

Background: It is important to understand the risk of thromboembolism and bleeding in
patients with nonvalvular atrial fibrillation (NVAF) receiving direct oral anticoagulants; …

Aims The EXPAND study examined the real-world efficacy and safety of rivaroxaban for the
prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular …

Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Background: Low-dose prescription of rivaroxaban was common among patients with atrial
fibrillation (AF) in Asia. However, the benefits and harms of rivaroxaban at a low dosage in …

Background and Purpose—In the daily practice, low-dose nonvitamin K antagonist oral
anticoagulants are commonly used among Asian patients with atrial fibrillation (AF). The aim …

Introduction: Prior stroke is a risk factor for stroke and bleeding during anticoagulation in
patients with atrial fibrillation (AF). Although rivaroxaban is widely prescribed to reduce their …